Synthesis and Mechanism of p53-MDM2 Inhibitors with Heterocyclic Structures: A Focused Review

被引:0
|
作者
Ji, Li-Tao [1 ]
Zhang, Wenjing [1 ]
Zhang, Yi [1 ]
Zhao, Su [1 ]
Long, Hai-Tao [1 ]
Qin, Li-Qing [1 ]
Tian, Jia-Cheng [1 ]
Li, Hong-Zhang [1 ]
Zhu, Dan-Xue [1 ]
Zhou, Yan [1 ]
Lu, Yi-Duo [1 ]
Wang, Zhen-Chao [1 ,2 ,3 ]
Li, Cheng-Peng [1 ,2 ,3 ]
机构
[1] Guizhou Univ, Coll Pharm, Guiyang 550025, Guizhou, Peoples R China
[2] Minist Educ, State Key Lab Breeding Base Green Pesticide & Agr, Key Lab Green Pesticide & Agr Bioengn, Guiyang 550025, Peoples R China
[3] Guizhou Univ, Guizhou Engn Lab Synthet Drugs, Guiyang 550025, Peoples R China
来源
CHEMISTRYSELECT | 2023年 / 8卷 / 45期
关键词
Small molecule; heterocyclic compounds; p53-MDM2; cancer; synthesis method; SMALL-MOLECULE INHIBITORS; PROTEIN-PROTEIN INTERACTION; STRUCTURE-BASED DESIGN; BIOLOGICAL EVALUATION; MDM2; INHIBITORS; SPIRO-OXINDOLES; CLINICAL-TRIALS; P53; PATHWAY; POTENT; DISCOVERY;
D O I
10.1002/slct.202302240
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
P53 gene mutation is one of the important causes in tumors. p53-MDM2 (murine double minute 2) inhibitors can interrupt p53-dependent gene transcription activity, and inhibit p53-mediated apoptosis, block p53-MDM2/MDMx interaction, and significantly reduce DNA formation. In this article, we focused on the synthesis methods about nutlins and other p53 small molecule inhibitors, in order to find potential new structure for novel p53 small molecule inhibitor synthesizing. Mutation of the p53 gene is among the most important causes of tumors. Inhibitors of p53-MDM2 can impede p53-dependent gene transcription, inhibit p53-mediated apoptosis, block p53-MDM2/MDMx interaction, and significantly reduce DNA formation. In this review we discuss the synthesis of nutlins and other small-molecule p53 inhibitors, with an aim to inspire new structures and methods for the synthesis of future small-molecule p53 inhibitors.+image
引用
收藏
页数:16
相关论文
共 50 条
  • [21] The Therapeutic Potential of Spirooxindoles in Cancer: A Focus on p53-MDM2 Modulation
    Girgis, Adel S.
    Zhao, Yujun
    Nkosi, Angel
    Ismail, Nasser S. M.
    Bekheit, Mohamed S.
    Aboshouk, Dalia R.
    Aziz, Marian N.
    Youssef, M. Adel
    Panda, Siva S.
    PHARMACEUTICALS, 2025, 18 (02)
  • [22] Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives as Novel Inhibitors of p53-MDM2 Protein-Protein Interaction
    Zhuang, Chunlin
    Miao, Zhenyuan
    Zhu, Lingjian
    Dong, Guoqiang
    Guo, Zizhao
    Wang, Shengzheng
    Zhang, Yongqiang
    Wu, Yuelin
    Yao, Jianzhong
    Sheng, Chunquan
    Zhang, Wannian
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) : 9630 - 9642
  • [23] The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction
    Furet, Pascal
    Chene, Patrick
    De Pover, Alain
    Valat, Therese Stachyra
    Lisztwan, Joanna Hergovich
    Kallen, Joerg
    Masuya, Keiichi
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (10) : 3498 - 3502
  • [24] Small-Molecule Inhibitors of the p53-MDM2 Interaction
    Vu, Binh T.
    Vassilev, Lyubomir
    SMALL-MOLECULE INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS, 2011, 348 : 151 - 172
  • [25] Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode
    Gessier, Francois
    Kallen, Joerg
    Jacoby, Edgar
    Chene, Patrick
    Stachyra-Valat, Therese
    Ruetz, Stephan
    Jeay, Sebastien
    Holzer, Philipp
    Masuya, Keiichi
    Furet, Pascal
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (17) : 3621 - 3625
  • [26] Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors
    Hu, Chunqi
    Li, Xin
    Wang, Weisi
    Zhang, Lei
    Tao, Lulu
    Dong, Xiaowu
    Sheng, Rong
    Yang, Bo
    Hu, Yongzhou
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (18) : 5454 - 5461
  • [27] Design and synthesis of new substituted spirooxindoles as potential inhibitors of the MDM2-p53 interaction
    Barakat, Assem
    Islam, Mohammad Shahidul
    Ghawas, Hussien Mansur
    Al-Majid, Abdullah Mohammed
    El-Senduny, Fardous F.
    Badria, Farid A.
    Elshaier, Yaseen A. M. M.
    Ghabbour, Hazem A.
    BIOORGANIC CHEMISTRY, 2019, 86 : 598 - 608
  • [28] Small-Molecule Inhibitors of p53-MDM2 Interaction: the 2006-2010 Update
    Millard, Melissa
    Pathania, Divya
    Grande, Fedora
    Xu, Shili
    Neamati, Nouri
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (06) : 536 - 559
  • [29] Prospective virtual screening for novel p53-MDM2 inhibitors using ultrafast shape recognition
    Patil, Sachin P.
    Ballester, Pedro J.
    Kerezsi, Cassidy R.
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2014, 28 (02) : 89 - 97
  • [30] Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres
    Gonzalez, Ana Z.
    Li, Zhihong
    Beck, Hilary P.
    Canon, Jude
    Chen, Ada
    Chow, David
    Duquette, Jason
    Eksterowicz, John
    Fox, Brian M.
    Fu, Jiasheng
    Huang, Xin
    Houze, Jonathan
    Jin, Lixia
    Li, Yihong
    Ling, Yun
    Lo, Mei-Chu
    Long, Alexander M.
    McGee, Lawrence R.
    McIntosh, Joel
    Oliner, Jonathan D.
    Osgood, Tao
    Rew, Yosup
    Saiki, Anne Y.
    Shaffer, Paul
    Wortman, Sarah
    Yakowec, Peter
    Yan, Xuelei
    Ye, Qiuping
    Yu, Dongyin
    Zhao, Xiaoning
    Zhou, Jing
    Olson, Steven H.
    Sun, Daqing
    Medina, Julio C.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (07) : 2963 - 2988